Sarepta declines as worries about future gene therapy findings surface.
Sarepta Therapeutics shares slumped 11% on Friday as some analysts voiced concerns…
Sarepta’s gene therapy for rare muscular dystrophy in some children has received US FDA approval.
The U.S. drug regulator on Thursday granted accelerated approval to Sarepta Therapeutics'…